Fmr Boss Sheds Light on Lek Takeover, Says Price Fair
Ljubljana, 29 November - Metod Dragonja, who headed drug company Lek when it was sold to Swiss pharmaceutical giant Novartis, told a parliamentary inquiry commission on Thursday that the decision for the 2002 sale was based on corporate interests and that the final price of SIT 105,000 per share was adequate at the time and place.
Ljubljana
Metod Dragonja, the former CEO of drug company Lek, discussing the 2002 takeover of Lek by Novartis before a parliamentary commission probing the sale of state stakes in companies.
Photo: Domen Groegl/STA
Ljubljana
Metod Dragonja, the former CEO of drug company Lek, discussing the 2002 takeover of Lek by Novartis before a parliamentary commission probing the sale of state stakes in companies.
Photo: Domen Groegl/STA
Ljubljana
Metod Dragonja, the former CEO of drug company Lek, discussing the 2002 takeover of Lek by Novartis before a parliamentary commission probing the sale of state stakes in companies.
Photo: Domen Groegl/STA
Ljubljana
Metod Dragonja, the former CEO of drug company Lek, discussing the 2002 takeover of Lek by Novartis before a parliamentary commission probing the sale of state stakes in companies.
Photo: Domen Groegl/STA
Ljubljana
Metod Dragonja (right), the former CEO of drug company Lek, quizzed about the takeover of Lek by Branko Marinic, the head of the parliamentary commission probing a sale of state stakes in companies.
Photo: Domen Groegl/STA
Ljubljana
Metod Dragonja, the former CEO of drug company Lek, before a hearing at the parliamentary commission probing a sale of state stakes in companies.
Photo: Domen Groegl/STA
Ljubljana
Metod Dragonja, the former CEO of drug company Lek, before a hearing at the parliamentary commission probing a sale of state stakes in companies.
Photo: Domen Groegl/STA
The rest of this news item is available to subscribers.
The news item consists of 2.435 characters (without spaces) or 475 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.